Compare VTRS & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | ALGN |
|---|---|---|
| Founded | 1961 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.2B |
| IPO Year | N/A | N/A |
| Metric | VTRS | ALGN |
|---|---|---|
| Price | $10.96 | $157.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $11.17 | ★ $190.50 |
| AVG Volume (30 Days) | ★ 7.8M | 1.5M |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.16 |
| Revenue | ★ $14,124,400,000.00 | $3,982,622,000.00 |
| Revenue This Year | N/A | $2.58 |
| Revenue Next Year | $1.16 | $3.41 |
| P/E Ratio | ★ N/A | $30.46 |
| Revenue Growth | N/A | ★ 0.56 |
| 52 Week Low | $6.85 | $122.00 |
| 52 Week High | $13.13 | $246.19 |
| Indicator | VTRS | ALGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 73.38 |
| Support Level | $10.67 | $144.00 |
| Resistance Level | $10.93 | $152.99 |
| Average True Range (ATR) | 0.24 | 4.97 |
| MACD | 0.01 | 1.74 |
| Stochastic Oscillator | 90.23 | 92.40 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.